Provided by Tiger Trade Technology Pte. Ltd.

Altimmune, Inc.

3.88
+0.34009.60%
Post-market: 3.80-0.0800-2.06%19:59 EDT
Volume:5.34M
Turnover:20.09M
Market Cap:504.67M
PE:-3.88
High:3.89
Open:3.64
Low:3.61
Close:3.54
52wk High:7.73
52wk Low:2.90
Shares:130.07M
Float Shares:124.00M
Volume Ratio:1.29
T/O Rate:4.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9999
EPS(LYR):-0.9999
ROE:-50.57%
ROA:-28.17%
PB:2.24
PE(LYR):-3.88

Loading ...

BUZZ-Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug

Reuters
·
Jan 05

Altimmune Earns FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Reuters
·
Jan 05

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in Mash

THOMSON REUTERS
·
Jan 05

Altimmune Director Diane Jorkasky Acquires Common Shares

Reuters
·
Dec 30, 2025

Insider Buying: Altimmune Independent Chairman Bought US$52k Of Shares

Simply Wall St.
·
Dec 28, 2025

Altimmune Director Jerome Benedict Durso Reports Acquisition of Common Shares

Reuters
·
Dec 23, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Intuitive Machines, Palo Alto Networks, Redwire

Reuters
·
Dec 19, 2025

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Reuters
·
Dec 19, 2025

Altimmune Shares Climb 6.9% Premarket After Positive Trial Data

THOMSON REUTERS
·
Dec 19, 2025

Altimmune Reports Positive 48-Week Phase 2b Results for Pemvidutide in MASH Trial

Reuters
·
Dec 19, 2025

Altimmune Inc - Pemvidutide 1.8 Mg Dose Achieves 7.5% Weight Loss

THOMSON REUTERS
·
Dec 19, 2025

Altimmune Announces That Pemvidutide Achieved Key Measures of Success at 48 Weeks in Impact Phase 2B Mash Trial

THOMSON REUTERS
·
Dec 19, 2025

FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up

Reuters
·
Dec 12, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa Resources

Reuters
·
Dec 02, 2025

Altimmune CEO Vipin Garg to Step Down

MT Newswires Live
·
Dec 01, 2025

BUZZ-Altimmune falls as CEO Vipin Garg to step down

Reuters
·
Dec 01, 2025

BRIEF-Altimmune Announces CEO Transition, Succession Plan

Reuters
·
Dec 01, 2025

Altimmune Inc - Vipin Garg to Step Down as CEO Effective Jan 1, 2026

THOMSON REUTERS
·
Dec 01, 2025

Altimmune Inc - Vipin Garg to Serve as Advisor Through June 30, 2026

THOMSON REUTERS
·
Dec 01, 2025

Altimmune Inc - Jerry Durso to Assume Role of CEO and Retain Chairman Position

THOMSON REUTERS
·
Dec 01, 2025